EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

The Europe non-alcoholic steatohepatitis (NASH) biomarker market is set to project a CAGR of 19.55% during the forecast period, 2021-2028. The increasing prevalence of NASH, the rising treatment awareness, the availability of technologically advanced diagnosis devices, and the growing aging population are set to drive the market growth.

To learn more about this report, request a free sample copy

The Europe non-alcoholic steatohepatitis (NASH) biomarker market growth analysis includes the assessment of the United Kingdom, France, Poland, Russia, Italy, Germany, Belgium, and Rest of Europe. In Germany, the expectant increase in the number of non-alcoholic fatty liver disease (NAFLD) and NASH cases is attributed to the rising prevalence of obesity, metabolic syndrome, and diabetes. NASH and NAFLD are also evaluated to be the major causes of hepatocellular carcinoma and cirrhosis. Also, there has been a considerable increase in obesity, as per the WHO. The Statutory Health Insurance data also suggests a growing prevalence of diabetes. Such factors are projected to increase the market growth in Germany.

In the United Kingdom, the NASH cases are set to reach 3.9 million by 2030, as per the 2018 EMA Workshop on Liver Diseases data. Also, the NHS data suggests that one in every three people suffer from NAFLD. Liver disease results in death for more than 40 people every day in the UK. Obesity has also become a significant health concern, according to the OECD data. It is evaluated that one in every four adults is impacted by obesity. Clinical trials for NAFLD is second-highest in the UK, after the US. Such factors are expected to boost the market growth in the UK.

GENFIT SA is a biopharmaceutical company engaged in developing and discovering biomarkers and drugs in the therapeutic areas. The company prioritizes R&D to participate in the potential commercialization of treatment solutions and diagnostic tools to fight certain autoimmune, inflammatory diseases, specifically affecting the liver. It is headquartered in France.

 

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1.    KEY DRIVERS
      1. GROWING NASH AFFECTED POPULATION
      2. SURGING PREVALENCE OF OBESITY AND DIABETES
      3. INCREASING OCCURRENCE OF CHRONIC DISEASES
      4. SURGING AWARENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE
    2.    KEY RESTRAINTS
      1. SIDE-EFFECTS AND RISKS ASSOCIATED WITH NASH THERAPEUTICS
      2. LACK OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
  4. KEY ANALYTICS
    1.    PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER’S POWER
      4. SUPPLIER’S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  5. MARKET BY TYPE
    1. SERUM BIOMARKER
    2. HEPATIC FIBROSIS BIOMARKER
    3. APOPTOSIS BIOMARKER
    4. OXIDATIVE STRESS BIOMARKER
    5. OTHER TYPES
  6. MARKET BY END-USER
    1. PHARMA & CRO INDUSTRY
    2. DIAGNOSTIC LAB
    3. ACADEMIC RESEARCH KEY
    4. HOSPITAL
  7. GEOGRAPHICAL ANALYSIS
    1.    EUROPE
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5.    COUNTRY ANALYSIS
        1. GERMANY
        2. FRANCE
        3. THE UNITED KINGDOM
        4. ITALY
        5. RUSSIA
        6. BELGIUM
        7. POLAND
        8. REST OF EUROPE
  8. COMPETITIVE LANDSCAPE
    1.    KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2.    COMPANY PROFILE
      1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
      2. ASTRAZENECA
      3. BRISTOL-MYERS SQUIBB COMPANY
      4. GENFIT SA
      5. GILEAD SCIENCES INC
      6. MADRIGAL PHARMACEUTICALS
      7. MERCK & CO
      8. NOVARTIS AG
      9. NOVO NORDISK
      10. PFIZER INC
      11. SIEMENS HEALTHINEERS
      12. VIKING THERAPEUTICS
      13. ZYDUS CADILA
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER

TABLE 2: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: LEADING PLAYERS OPERATING IN EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020

FIGURE 6: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 7: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 8: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 9: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)

FIGURE 10: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)

FIGURE 11: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020

FIGURE 12: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)

FIGURE 13: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)

FIGURE 14: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)

FIGURE 15: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)

FIGURE 16: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 17: GERMANY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 18: FRANCE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 19: UNITED KINGDOM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 20: ITALY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 21: RUSSIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 22: BELGIUM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 23: POLAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

FIGURE 24: REST OF EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample